Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke: Results of a randomized, placebo-controlled, double-blind study

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 3, 2003, Pages 121-126

  Woessner, Ralph ^a   Grauer, Markus T ^a   Dieterich, Hans Jürgen ^b   Bepperling, Frank ^c   Baus, Daniela ^c   Kahles, Timo ^d   Georgi, Sven ^d   Bianchi, Oliver ^d   Morgenthaler, Martin ^a   Treib, Johannes ^a  

^a Westpfalz Klinikum GmbH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Fresenius Kabi Deutschland GmbH   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Blood pressure; Cardiac output; Hydroxyethyl starch; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMYLASE; BLOOD CLOTTING FACTOR 7; CLOPIDOGREL; HEPARIN; HETASTARCH;

ARTICLE; BLOOD PRESSURE; BORRELIA INFECTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYSTALLOID; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; FLOW RATE; HEART OUTPUT; HEMATOCRIT; HEMODYNAMICS; HEMOSTASIS; HUMAN; IATROGENIC DISEASE; LABORATORY TEST; LOW DRUG DOSE; PLASMA VISCOSITY; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAFETY;

BRAIN ISCHEMIA; CARDIAC OUTPUT; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; HEMODYNAMIC PROCESSES; HEMORHEOLOGY; HEMOSTASIS; HETASTARCH; HUMANS; ISOTONIC SOLUTIONS; PLASMA SUBSTITUTES; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 2542588612     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077819     Document Type: Article

References (23)

1. Baron J-F, Treib J (eds): Volume Replacement. Berlin, Springer, 1998.
2. Treib J (ed): Volume Therapy. Berlin, Springer, 2000.
3. Treib J, Grauer MT, Woessner R, Morgenthaler M: Treatment of stroke on an intensive stroke unit: A novel concept. Intensive Care Med 2000;26:1598-1611.
4. Mast H, Marx P: Neurological deterioration under isovolemic hemodilution with hydroxyethyl starch in acute cerebral ischemia. Stroke 1991;22:680-683.
5. Haemodilution in acute stroke: Results of the Italian haemodilution trial. Italian Acute Stroke Study Group. Lancet 1988;i:318-321.
6. Aichner FT, Fazekas F, Brainin M, Polz W, Mamoli B, Zeiler K: Hypervolemic hemodilution in acute ischemic stroke: The Multicenter Austrian Hemodilution Stroke Trial (MAHST). Stroke 1998;29:743-749.
7. Koller M, Haenny P, Hess K, Weniger D, Zangger P: Adjusted hypervolemic hemodilution in acute ischemic stroke. Stroke 1990;21: 1429-1434.
8. Strand T: Evaluation of long-term outcome and safety after hemodilution therapy in acute ischemic stroke. Stroke 1992;23:657-662.
9. Strand T, Asplund K, Eriksson S, Hägg E, Lithner F, Wester PO: A randomized controlled trial of hemodilution therapy in acute ischemic stroke. Stroke 1984;15:980-989.
10. Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. The Hemodilution in Stroke Study Group. Stroke 1989;20:317-323.
11. Kaplan S, Park TS, Gonzales E, Gidday J: Hydroxyethyl starch reduces leukocyte adherence and vascular injury in the newborn pig cerebral circulation after asphyxia. Stroke 2000;31:2218-2223.
12. Treib J, Baron JF, Grauer MT, Strauss RG: An international view of hydroxyethyl starches. Intensive Care Med 1999;25:258-268.
13. Treib J, Haass A, Pindur G: Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997;78:974-983.
14. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K: All medium starches are not the same: Influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions and coagulation. Transfusion 1996;36:450-455.
15. Treib J, Haass A, Pindur G, Seyfert UT, Treib W, Grauer MT, Jung F, Wenzel E, Schimrigk K: HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995;74:1452-1456.
16. Treib J, Haass A, Krammer I, Stoll M, Grauer MT, Schimrigk K: Cardiac output in patients with acute stroke. J Neurol 1996;243:575-578.
17. Rudolf J: Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: A randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002;14:33-41.
18. Waitzinger J, Bepperling F, Pabst G, Opitz J, Müller M, Baron JF: Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification (HES 130/0.4) after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998;16:151-160.
19. Waitzinger J, Bepperling F, Pabst G, Opitz J, Fackelmeyer A, Boldt J: Effect of a new hydroxyethyl starch (HES) specification (6% HES 130/0.4) on blood and plasma volumes after bleeding in 12 healthy male volunteers. Clin Drug Invest 1999;17:119-125.
20. Waitzinger J, Bepperling F, Pabst G, Opitz J: Hydroxyethyl starch (HES) [130/0.4], a new HES specification: Pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drug R D 2003;4:149-157.
21. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P: Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001;92:855-862.
22. 14C-labelled hydroxyethyl starch (HES 130/0.4) and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003;4:331-338.
23. Gröchenig E, Albegger K, Dieterich HJ, et al: Hydroxyethylstarch- related pruritus: A prospective multicenter investigation of 544 patients. Perfusion 1998;11:62-69.